Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.48
-C$0.02(-4.17%)
At close: 4:00 PM EDT
C$0.48
-C$0.02(-4.17%)
Day’s Range― - ―
52-Week RangeC$0.29 - C$0.94
Previous CloseN/A
Volume3.80K
Average Volume (3M)38.15K
Market Cap
C$31.70M
Enterprise ValueC$20.73
Total Cash (Recent Filing)C$4.37M
Total Debt (Recent Filing)C$515.57K
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding70,441,360
10 Day Avg. Volume21,608
30 Day Avg. Volume38,150
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage gives MustGrow greater financial flexibility than a heavily indebted company while it develops and commercializes its technologies. Lower debt obligations can reduce refinancing pressure and preserve capacity to fund regulatory, research, and commercialization activities.
Improved Gross MarginA gross margin near 53% indicates the company can retain meaningful value from revenue before operating costs. If maintained as commercialization develops, this provides a foundation for operating leverage, although current scale and overhead still prevent the margin improvement from producing profitability.
Scalable Licensing ModelA licensing-led model can allow MustGrow to monetize intellectual property without building a large direct-to-farm distribution operation. Partner manufacturing, registration, and sales could support broader reach while milestone and royalty structures may create operating leverage as adoption develops.
Bears Say
Sharp Revenue ContractionThe recent contraction shows that revenue generation remains inconsistent and has not yet established a durable growth trajectory. Continued weakness could slow regulatory and commercialization progress, reduce operating leverage, and make it harder for the company to absorb its fixed development costs.
Persistent Deep LossesLarge operating and net losses indicate that current revenue is far below the scale needed to cover research, regulatory, and corporate costs. Unless commercialization expands materially or expenses decline, ongoing losses could continue eroding equity and constrain strategic investment.
Ongoing Cash ConsumptionNegative operating and free cash flow means the business is consuming cash rather than internally funding its activities. Persistent cash use can increase reliance on external financing, potentially limiting flexibility and creating dilution or funding pressure while products progress toward commercialization.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.29 and its highest was C$0.94 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$31.70M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Dec 01, 2026 which is in 73 days.
How were MustGrow Biologics’s earnings last quarter?
MustGrow Biologics released its earnings results on Aug 27, 2026. The company reported C$0 earnings per share for the quarter.
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 70,441,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
MustGrow Biologics reported an EPS of C$0 in its last earnings report. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
MGRO Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―